Free Trial

West Pharmaceutical Services (WST) Stock Forecast & Price Target

West Pharmaceutical Services logo
$252.17 -0.98 (-0.39%)
Closing price 03:59 PM Eastern
Extended Trading
$252.14 -0.02 (-0.01%)
As of 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
2
Buy
7

Based on 9 Wall Street analysts who have issued ratings for West Pharmaceutical Services in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 2 have given a hold rating, 6 have given a buy rating, and 1 has given a strong buy rating for WST.

Consensus Price Target

$320.71
27.18% Upside
According to the 9 analysts' twelve-month price targets for West Pharmaceutical Services, the average price target is $320.71. The highest price target for WST is $400.00, while the lowest price target for WST is $245.00. The average price target represents a forecasted upside of 27.18% from the current price of $252.17.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for WST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WST Analyst Ratings Over Time

TypeCurrent Forecast
9/9/24 to 9/9/25
1 Month Ago
8/10/24 to 8/10/25
3 Months Ago
6/11/24 to 6/11/25
1 Year Ago
9/10/23 to 9/9/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$320.71$320.71$332.50$442.75
Forecasted Upside27.18% Upside32.91% Upside48.46% Upside46.65% Upside
Consensus RatingModerate BuyModerate BuyBuyModerate Buy

WST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

WST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

West Pharmaceutical Services Stock vs. The Competition

TypeWest Pharmaceutical ServicesMedical CompaniesS&P 500
Consensus Rating Score
2.89
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside26.53% Upside17,263.07% Upside10.49% Upside
News Sentiment Rating
Very Positive News

See Recent WST News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
7/25/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
John Sourbeer
John Sourbeer
Not Rated
Boost TargetBuy$285.00 ➝ $320.00+19.29%
7/25/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$275.00 ➝ $350.00+33.17%
6/24/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Luke Sergott
Luke Sergott
Not Rated
Initiated CoverageEqual Weight$245.00+12.88%
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
4/21/2025Stephens
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
2/14/2025KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$470.00 ➝ $325.00+46.46%
2/14/2025Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy$250.00+25.38%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$350.00 ➝ $355.00+8.95%
12/13/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoveragePeer Perform
2/7/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy$323.00 ➝ $536.00+34.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:05 PM ET.


Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 7, 2025. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com.

West Pharmaceutical Services
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

  • The company recently reported strong quarterly earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial health and operational efficiency.
  • West Pharmaceutical Services, Inc. has a solid revenue growth of over 9% year-over-year, showcasing its ability to expand its market presence and increase sales.
  • The current stock price is around $320, reflecting positive market sentiment and potential for further appreciation based on analyst ratings.
  • The company has a low debt-to-equity ratio, suggesting a conservative approach to leverage, which can be appealing to risk-averse investors.
  • Recent upgrades from multiple analysts, including a notable increase in price targets, indicate strong confidence in the company's future performance.

West Pharmaceutical Services
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

  • The stock has a relatively low dividend yield of 0.4%, which may not attract income-focused investors looking for higher returns from dividends.
  • Despite positive growth, the company operates in a competitive market, which could pressure margins and impact future profitability.
  • Analysts have mixed ratings, with some holding a "hold" position, indicating uncertainty about the stock's short-term performance.
  • The company's current ratio, while healthy, may suggest that it is holding onto excess cash rather than reinvesting it into growth opportunities.
  • Market volatility can impact stock performance, and any downturn in the broader market could adversely affect West Pharmaceutical Services, Inc.'s stock price.

WST Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for West Pharmaceutical Services is $320.71, with a high forecast of $400.00 and a low forecast of $245.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 2 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WST shares.

According to analysts, West Pharmaceutical Services's stock has a predicted upside of 27.18% based on their 12-month stock forecasts.

West Pharmaceutical Services has been rated by research analysts at Barclays, Evercore ISI, and UBS Group in the past 90 days.

Analysts like West Pharmaceutical Services more than other "medical" companies. The consensus rating score for West Pharmaceutical Services is 2.89 while the average consensus rating score for "medical" companies is 2.78. Learn more on how WST compares to other companies.


This page (NYSE:WST) was last updated on 9/9/2025 by MarketBeat.com Staff
From Our Partners